INO Quote, Financials, Valuation and Earnings

CervoMed has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of --. Inovio Pharmaceuticals's return on equity of -119.02% beat CervoMed's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 307.99%. On the other hand CervoMed has an analysts' consensus of $15.83 which suggests that it could grow by 9.01%. Given that Inovio Pharmaceuticals has higher upside potential than CervoMed, analysts believe Inovio Pharmaceuticals is more attractive than CervoMed.

Inovio Pharmaceuticals has a beta of 0.917, which suggesting that the stock is 8.256% less volatile than S&P 500. In comparison CervoMed has a beta of 1.837, suggesting its more volatile than the S&P 500 by 83.67%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CervoMed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. CervoMed pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are larger than CervoMed quarterly revenues of --. Inovio Pharmaceuticals's net income of -$19.4M is lower than CervoMed's net income of -$6.7M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while CervoMed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 23.47x for CervoMed. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of -91.76%. Inovio Pharmaceuticals's return on equity of -119.02% beat Novavax's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 307.99%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 115.88%. Given that Inovio Pharmaceuticals has higher upside potential than Novavax, analysts believe Inovio Pharmaceuticals is more attractive than Novavax.

Inovio Pharmaceuticals has a beta of 0.917, which suggesting that the stock is 8.256% less volatile than S&P 500. In comparison Novavax has a beta of 2.916, suggesting its more volatile than the S&P 500 by 191.569%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than Novavax quarterly revenues of $88.3M. Inovio Pharmaceuticals's net income of -$19.4M is higher than Novavax's net income of -$81M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.75x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of 35.65%. Inovio Pharmaceuticals's return on equity of -119.02% beat Protalix BioTherapeutics's return on equity of 8.75%.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 307.99%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 482.33%. Given that Protalix BioTherapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 0.917, which suggesting that the stock is 8.256% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Inovio Pharmaceuticals's net income of -$19.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 3.87x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -16566.39% compared to Inovio Pharmaceuticals's net margin of -309.84%. Inovio Pharmaceuticals's return on equity of -119.02% beat Sangamo Therapeutics's return on equity of -217.48%.

Inovio Pharmaceuticals has a consensus price target of $7.83, signalling upside risk potential of 307.99%. On the other hand Sangamo Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 476.97%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 0.917, which suggesting that the stock is 8.256% less volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.44%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $117K, which are smaller than Sangamo Therapeutics quarterly revenues of $7.6M. Inovio Pharmaceuticals's net income of -$19.4M is higher than Sangamo Therapeutics's net income of -$23.4M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 3.03x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.